Caregen Co., Ltd. (KOSDAQ:214370)
South Korea · Delayed Price · Currency is KRW | Market Cap | 3.13T |
| Revenue (ttm) | 81.08B |
| Net Income (ttm) | 29.99B |
| Shares Out | 48.87M |
| EPS (ttm) | 612.12 |
| PE Ratio | 104.72 |
| Forward PE | n/a |
| Dividend | 640.00 (1.08%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 197,475 |
| Average Volume | 141,285 |
| Open | 58,000 |
| Previous Close | 59,400 |
| Day's Range | 57,800 - 65,300 |
| 52-Week Range | 16,130 - 71,300 |
| Beta | 0.61 |
| RSI | 56.55 |
| Earnings Date | Aug 7, 2025 |
About Caregen
Caregen Co., Ltd., a biotechnology company, researches, develops, and commercializes biomimetic peptides worldwide. The company offers filler products under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names; skin care products under the Dermaheal, PURILUX whitening, Pim-Pim-Paul, and Neovert names; scalp care products under the Renokin and Pelo Baum names; and healthy foods under the proGsterol name. It is also developing medicines for COVID-19 treatment, wet macular degeneration, dry macular degeneration, antivira... [Read more]
Financial Performance
In 2024, Caregen's revenue was 82.59 billion, an increase of 4.26% compared to the previous year's 79.21 billion. Earnings were 32.31 billion, a decrease of -19.07%.
Financial StatementsNews
Akums Drugs shares surge 5% after signing Master Sales Agreement with Caregen
Akums Drugs and Pharmaceuticals saw a 5% jump in its stock price after signing an exclusive Master Sales Agreement with South Korea-based Caregen Co., Ltd. The deal gives Akums exclusive rights to pac...
Akums Drugs signs Master Sales Agreement with Caregen for Indian Nutraceutical market expansion
Akums Drugs and Pharmaceuticals Ltd., a leading name in the pharmaceutical industry, has signed an exclusive Master Sales Agreement with South Korea’s Caregen Co., Ltd. This partnership grants Akums e...